33,105 Shares in Pfizer Inc. $PFE Purchased by Mangrove Partners IM LLC

Mangrove Partners IM LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 33,105 shares of the biopharmaceutical company’s stock, valued at approximately $844,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares during the last quarter. Norges Bank acquired a new position in Pfizer in the second quarter valued at approximately $2,270,157,000. Fisher Asset Management LLC lifted its holdings in Pfizer by 1.9% in the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after acquiring an additional 897,786 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Pfizer by 2.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after acquiring an additional 1,135,457 shares during the period. Finally, Legal & General Group Plc increased its stake in Pfizer by 8.6% during the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after acquiring an additional 3,296,415 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Pfizer Trading Down 1.0%

PFE opened at $26.60 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $26.50 and a 200-day simple moving average of $25.52. The firm has a market cap of $151.23 billion, a P/E ratio of 19.56 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the previous year, the business earned $0.63 EPS. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

PFE has been the topic of a number of research analyst reports. Barclays assumed coverage on Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price on the stock. Bank of America cut their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a report on Monday, March 2nd. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. Finally, Royal Bank Of Canada started coverage on shares of Pfizer in a research note on Tuesday, February 24th. They set an “underperform” rating and a $25.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $28.05.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.